Dernières nouvelles pour Battalion Oil (AMEX:BATL) Stock

Battalion Oil

Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.

Battalion Oil Corp

WIIM

OKLO

OKLO stock has given up its prior gain. Oklo shares were trading higher after the company announced its subsidiary Atomic Alchemy commenced site characterization work at a potential location for a commercial radioisotope production facility in Idaho.

<a href="https://digiday.com/media-buying/omnicom-partnerships-with-amazon-and-meta-to-build-on-live-content-and-live-shopping/" title="https://digiday.com/media-buying/omnicom-partnerships-with-amazon-and-meta-to-build-on-live-content-and-live-shopping/">https://digiday.com/media-buying/omnicom-partnerships-with-amazon-and-meta-to-build-on-live-content-and-live-shopping/</a>

News

AMZN

'Omnicom Partners With Amazon And Meta To Build On Live Content And Live Shopping' - Digiday

Purpose Investments Inc. has secured final regulatory approval from the Ontario Securities Commission (OSC) to launch the Purpose ETF, which will begin trading on the Toronto Stock Exchange (TSX) on Wednesday, June 18, <a href="https://www.benzinga.com/topic/xrp">under the ticker XRPP.</a>
This <a href="https://www.purposeinvest.com/thoughtful/purpose-xrp-etf-receives-osc-receipt-set-to-launch-on-tsx-on-wednesday-june-18-2025">marks </a>Canada's first spot XRP exchange-traded fund, offering investors direct exposure to XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), the native token of Ripple, a blockchain designed for fast and cost-effective cross-border payments.
The ETF represents the latest addition to Purpose's established suite of digital asset offerings, following its pioneering spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ETFs.
Vlad Tasevski, chief innovation officer at Purpose, stated, "The OSC's granting of a receipt for the Purpose XRP ETF prospectus reinforces Canada's global leadership in building a regulated digital asset ecosystem."
The Purpose XRP ETF will be available in three formats: CAD-hedged (XRPP), CAD non-hedged (XRPP.B), and US dollar (XRPP.U) units. 
Investors can hold the ETF in registered accounts like Tax-Free Savings Accounts (TFSAs) and Registered Retirement Savings Plans (RRSPs), offering tax advantages and simplifying access to XRP without managing private wallets. 
The fund's structure tracks XRP's price movements, minus management fees, providing a straightforward investment option for both retail and institutional investors.
Also Read: <a href="https://www.benzinga.com/crypto/25/06/45970737/franklin-templeton-exec-europe-stuck-in-the-slow-lane-of-crypto-regulation">Franklin Templeton Exec: Europe Stuck In The Slow Lane Of Crypto Regulation</a>
Canada's stance on crypto ETFs contrasts with slower regulatory progress in other regions, particularly the United States, where XRP ETF applications remain under review.
Several firms have pursued XRP and other cryptocurrency ETFs, particularly in the U.S., though none have yet been approved. 
In January 2025, European asset manager CoinShares filed for an XRP ETF, though details on its listing venue and asset size remain undisclosed. 
Concurrently, Bitwise submitted an XRP ETF application to the U.S. Securities and Exchange Commission (SEC), with a decision expected in June 2025. 
ProShares also filed for an XRP ETF, requesting a final SEC decision by June 25, 2025, after which the SEC cannot delay further. 
After the SEC approved spot Bitcoin ETFs in January and later Ethereum ETFs in 2024, former Chair Gary Gensler resigned at the start of 2025. Since then, the regulatory climate under President Donald Trump has become more crypto‑friendly, prompting new filings such as a combined Bitcoin‑Ether ETF.
Ripple's legal victory against the SEC, including a $50 million settlement in March 2025 (despite a temporary rejection of a joint motion in May), has further fueled optimism for U.S. XRP ETFs. 
Research by Kaiko indicates XRP has more ETF filings than other altcoins like Solana, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), and Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>), reflecting strong market interest. 
Additionally, Grayscale's XRP Trust (XRX) offers indirect XRP exposure in the U.S., and there is speculation that it may convert to an ETF if regulatory hurdles clear.
Read Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45962262/jpmorgan-files-trademark-jpmd-crypto-trading-digital-asset-services">Dimon Called Crypto A &#8216;Ponzi Scheme&#8217;—Now JPMorgan Is Building JPMD To Trade It</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

ETFs

$BTC

$DOGE

$LTC

$SOL

$XRP

XRP ETF To Debut In Canada, Setting The Stage For US Showdown

Morgan Stanley analyst Matthew Harrison downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Overweight to Equal-Weight and lowers the price target from $113 to $40.

Downgrades

Price Target

Analyst Ratings

SRPT

Morgan Stanley Downgrades Sarepta Therapeutics to Equal-Weight, Lowers Price Target to $40

A New Jersey teenager flunked his driver's test—allegedly not for how he drove, but <a href="https://www.benzinga.com/topic/electric-vehicle">for what he drove</a>.
What Happened: High school junior Lochlan Keefer used his family's Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model Y during his May 16 driver's training road test in Cherry Hill, New Jersey. But a state examiner failed the student and claimed the car's advanced features, including regenerative braking and alleged driver-assistance systems, gave him an unfair edge.
"Had the parking and stopping assistance on never stepped on the brake to stop his self let the vehicle stop itself," the examiner noted on the testing slip as <a href="https://www.nj.com/news/2025/06/my-son-flunked-his-road-test-because-he-was-driving-a-tesla-dad-says.html?outputType=amp">reported </a>by NJ.com.
James Keefer, the student&#8217;s father, explained to the instructor that the Model Y features weren&#8217;t being used. 
"The examiner accused my son of using driver assistance features simply because he parallel parked smoothly on the first try," the father said. "He was specifically accused of using paid parking-assist and driving features, which we do not subscribe to."
The vehicle has "regenerative braking," a feature Keefer&#8217;s son offered to disable multiple times but was told it wasn't necessary by the instructor. "But after the test – despite no safety issues and no actual driving faults – the examiner claimed driver assistance was active and retroactively said it should have been off.&#8221;
The student driver was told to wait 14 days to retake the test without the braking system. A supervisor supported the instructor's failure decision.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45945298/tesla-model-3-on-fsd-mode-struck-by-train-after-getting-trapped-on-railroad-tracks-report">Tesla Model 3 On FSD Mode Struck By Train After Getting Trapped On Railroad Tracks: Report</a>
The father said he wasn't shown any policy they had violated and claimed the supervisor became "belligerent and unprofessional."
Keefer also claims he heard an Motor Vehicle Commission (MVC) employee call him a "Republican" due to driving a Tesla vehicle associated with Elon Musk.
The family filed a discrimination complaint against the MVC.
Lochlan took his road test again on May 30 in Delanco and passed without disabling the regenerative braking.
"The examiner at Delanco was fully aware of the regenerative braking feature and had no issues conducting the test under these conditions, further illustrating the inconsistency in interpretation or enforcement of non-existent MVC policies regarding regenerative braking," James Keefer said.
Why It's Important: Families looking to get their kids driving on their own may want to avoid bringing a Tesla vehicle to the road test. The report said student drivers in California and Arizona have also failed tests due to regenerative braking features.
As vehicles become more advanced and have self-driving or driver-assistance features, driver's training programs need to update their rules or make it known that teenagers can't pass their tests while using a vehicle with these features.
The Model Y is one of the <a href="https://www.benzinga.com/news/25/01/42986863/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestsel">top-selling vehicles</a> globally each year and the top-selling electric vehicle of all time.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44937440/tesla-q1-earnings-highlights-revenue-miss-eps-miss-tariff-landscape-and-changing-political-sentiment-cloud-guidance">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track&nbsp;</a></li>
</ul>
Image: Shutterstock

TSLA

Tesla Vehicles Not Meant For Driver's Training? High Schooler Fails Road Test

<a href="https://www.bloomberg.com/news/articles/2025-06-17/kayne-anderson-raises-nearly-1-7-billion-for-property-debt-fund?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-17/kayne-anderson-raises-nearly-1-7-billion-for-property-debt-fund?embedded-checkout=true</a>

General

KBDC

'Kayne Anderson Raises Nearly $1.7 Billion for Property Debt Fund'- Bloomberg

Baird analyst Ben Kallo maintains MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) with a Outperform and raises the price target from $30 to $38.

Baird Maintains Outperform on MP Materials, Raises Price Target to $38

GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) has outperformed the market over the past 5 years by 8.34% on an annualized basis producing an average annual return of 22.47%. Currently, GFL Environmental has a market capitalization of $18.07 billion. 
Buying $1000 In GFL: If an investor had bought $1000 of GFL stock 5 years ago, it would be worth $2,682.26 today based on a price of $49.28 for GFL at the time of writing.
<h3>GFL Environmental's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750174215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $60 to $30.

Baird Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $30

CAVA

Live On CNBC, CAVA Group CEO Brett Schulman Discusses Growth & Expansion

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) with a Buy rating and announces Price Target of $5.

Initiation

LUCID CAPITAL MARKETS Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $5

Amendment to Agreement with Seller Reduces Cash Obligation by $1.5 million; and Reduces Stock Requirement by 1.5 million Shares; Closing Expected by end of July 2025
HOUSTON, TX / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 17, 2025 / EON Resources Inc. (NYSE:<a href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) ("EON" or the "Company") announced that on June 13, 2025 the Company amended the Purchase, Sale, Termination and Exchange Agreement dated February 10, 2025 with Pogo Royalty, LLC ("Pogo" or "Seller"). Closing on the terms of the amendment will result in further improvement to the restructuring of EON's balance sheet by reducing the total cash obligation of the Company to Seller by $1.5 million (from $22.0 million down to $20.5 million), and reducing the stock issuance consideration to Seller by 1.5 million shares of Class A Common Stock (down from 3.0 million Class A shares). A copy of the <a href="https://pr.report/bm38">Original Agreement Press Release</a> dated February 11, 2025 appears on the Company's website.

EONR

EON Resources Amends Agreement With Pogo Royalty To Cut Cash Payment By $1.5M And Reduce Stock Issuance By 1.5M Shares; Expected By End Of July 2025

Raymond James analyst Steve Hansen downgrades Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) from Outperform to Market Perform and maintains the price target from $68 to $68.

Raymond James Downgrades Nutrien to Market Perform, Maintains Price Target to $68

Pivotal Research analyst Jeffrey Wlodarczak maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $800 to $900.

SPOT

Pivotal Research Maintains Buy on Spotify Technology, Raises Price Target to $900

RBNE

Robin Energy Shares Resume Trade

Macro Economic Events

Global

Economics

Reuters Reports Mitsubishi Motors Hiking Prices On New U.S. Vehicles By Average Of 2.1% Effective Wednesday

Shares of airline stocks are trading lower amid macro uncertainty and rising oil prices after President Trump denied working on a ceasefire and said everyone should evacuate Tehran.

Piper Sandler analyst David Amsellem downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Overweight to Neutral and lowers the price target from $9 to $8.5.

SAGE

Piper Sandler Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $8.5

MENS

Jyong Biotech Shares Halted On Circuit Breaker To The Downside At $16.05/Share

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $215 price target.

Comments

Battalion Oil

Actualités

Dernières nouvelles pour Battalion Oil (AMEX:BATL) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL